(19)
(11) EP 3 625 263 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
28.05.2025 Bulletin 2025/22

(45) Mention of the grant of the patent:
09.04.2025 Bulletin 2025/15

(21) Application number: 18870270.8

(22) Date of filing: 29.10.2018
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
G01N 33/574(2006.01)
 A61K 39/395(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 35/00; A61P 37/06
(86) International application number:
PCT/US2018/058028
(87) International publication number:
WO 2019/084553 (02.05.2019 Gazette 2019/18)

(54)

ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF

ANTI-GALECTIN-9-ANTIKÖRPER UND VERWENDUNGEN DAVON

ANTICORPS ANTI-GALECTINE-9 ET LEURS UTILISATIONS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 27.10.2017 US 201762578111 P
01.05.2018 US 201862665175 P
25.09.2018 US 201862736317 P

(43) Date of publication of application:
25.03.2020 Bulletin 2020/13

(60) Divisional application:
25168928.7

(73) Proprietors:
  • New York University
    New York City, NY 10012 (US)
  • PureTech LYT, Inc.
    Boston, MA 02210 (US)

(72) Inventors:
  • KOIDE, Shohei
    New York, NY 10017 (US)
  • MILLER, George
    Englewood, NJ 07631 (US)
  • KOIDE, Akiko
    New York, NY 10017 (US)
  • CHEN, Linxiao
    Doylestown, PA 18901 (US)
  • FILIPOVIC, Aleksandra
    London W6 8JA (GB)
  • ELENKO, Eric
    Boston, MA 02110 (US)
  • BOLEN, Joseph
    Boston, MA 02116 (US)

(74) Representative: FRKelly 
Waterways House Grand Canal Quay
Dublin D02 PD39
Dublin D02 PD39 (IE)


(56) References cited: : 
WO-A2-2016/061504
US-A1- 2017 283 499
 US-A1- 2014 242 095
   
  • CLÉMENT BARJON ET AL: "A novel monoclonal antibody for detection of galectin-9 in tissue sections: application to human tissues infected by oncogenic viruses", INFECTIOUS AGENTS AND CANCER, BIOMED CENTRAL LTD, LO, vol. 7, no. 1, 17 July 2012 (2012-07-17), pages 16, XP021116920, ISSN: 1750-9378, DOI: 10.1186/1750-9378-7-16
  • TUERECI O ET AL: "MOLECULAR DEFINITION OF A NOVEL HUMAN GALECTIN WHICH IS IMMUNOGENIC IN PATIENTS WITH HODGKIN'S DISEASE", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 272, no. 10, 7 March 1997 (1997-03-07), pages 6416 - 6422, XP002065487, ISSN: 0021-9258, DOI: 10.1074/JBC.272.10.6416
  • CLAIRE LHUILLIER ET AL: "Characterization of neutralizing antibodies reacting with the 213-224 amino-acid segment of human galectin-9", PLOS ONE, vol. 13, no. 9, 11 September 2018 (2018-09-11), pages e0202512, XP055538758, DOI: 10.1371/journal.pone.0202512
  • TURECI ET AL.: "Molecular Definition of a Novel Human Galectin Which Is Immunogenic in Patients with Hodgkin's Disease", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 10, 7 March 1997 (1997-03-07), pages 6416 - 6422, XP002272062, DOI: doi:10.1074/jbc.272.10.6416
  • BARJON ET AL.: "A novel monoclonal antibody for detection of galectin-9 in tissue sections: application to human tissues infected by oncogenic viruses", INFECTIOUS AGENTS AND CANCER, vol. 7, 17 July 2012 (2012-07-17), XP021116920, DOI: doi:10.1186/1750-9378-7-16
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).